A compound preparation based on the relationship between traditional Chinese medicine's spleen and stomach theory and gut microbiota balance, its preparation method, and its application.

By combining traditional Chinese medicine's theory of spleen and stomach with a compound preparation for balancing intestinal flora, and using prebiotics, probiotics, and food-grade ingredients, this technology solves the problems of spleen and stomach regulation and intestinal flora imbalance in existing technologies. It achieves rapid and precise regulation of intestinal flora and enhancement of spleen and stomach function, making it suitable for the needs of the Chinese population.

CN123100839APending Publication Date: 2026-11-17BEIJING SCITOP BIO TECH CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202611252103.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-18
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing traditional Chinese medicine treatments and probiotic preparations have problems such as low efficiency and insufficient applicability in improving spleen and stomach function and intestinal flora imbalance, especially in terms of compatibility and stability for the Chinese population.

Method used

Combining traditional Chinese medicine theories on the spleen and stomach with gut microbiota balance, this product utilizes prebiotics, probiotics, and food-medicine homologous ingredients to prepare a compound preparation through decoction, concentration, and drying processes. It contains prebiotics such as xylooligosaccharides, resistant dextrin, and fructooligosaccharides, probiotics such as Lactobacillus paracasei and Bifidobacterium animalis, and food-medicine homologous ingredients such as hawthorn, tangerine peel, and codonopsis pilosula. This results in a triple synergistic effect: prebiotics improve the gut microenvironment, probiotics regulate the microbiota structure, and food-medicine homologous ingredients strengthen the spleen and replenish qi.

Benefits of technology

It significantly improves gut microbiota imbalance, enhances spleen and stomach function, increases probiotic colonization rate, and forms a positive cycle. Its effects are superior to those of a single module. It is suitable for the constitution of the Chinese population, has high safety, and is widely applicable.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention is titled "A Compound Preparation Based on the Relationship between Traditional Chinese Medicine's Spleen and Stomach Theory and Intestinal Microbiota Balance, and Its Preparation Method and Application," belonging to the field of functional food technology, such as functional foods that improve spleen and stomach function, regulate intestinal microbiota, and assist in weight management. The technical problem to be solved is to address the shortcomings of existing products, such as the lack of a synergistic regulatory system and the inability to eradicate the vicious cycle of spleen deficiency and microbiota imbalance. This invention provides a herbal compound probiotic preparation, comprising, by weight: 5-30 parts prebiotics (xylooligosaccharides, resistant dextrin, fructooligosaccharides, polydextrose, isomaltitol, inulin), 1-15 parts probiotics (Lactobacillus casei, Bifidobacterium lactis subsp. lactis, Bifidobacterium longum subsp. infantis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum subsp. longum, Lactobacillus gasseri, Bifidobacterium lactis subsp. lactis), and 5-25 parts medicinal and edible raw materials (hawthorn, tangerine peel, codonopsis, malt, poria cocos, dried ginger, and licorice).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of functional food technology, specifically to a compound preparation based on the theory of spleen and stomach in traditional Chinese medicine and the relationship between intestinal flora balance and its preparation method and application. Background Technology

[0002] With the fast pace of modern life, digestive disorders and related intestinal problems are becoming increasingly common. Current market solutions mainly fall into two categories: Traditional Chinese herbal medicine / food-medicine homology compound formulas: mostly based on the principles of strengthening the spleen, promoting digestion, and removing dampness (such as Baohe Wan, Shenling Baizhu San, etc.), focusing on overall conditioning from the perspective of TCM syndromes, but the effect is relatively slow, and the mechanism of action for the specific target of "intestinal flora imbalance" as defined by modern medicine is unclear and lacks support from modern biological evidence.

[0003] Microecological preparations, including probiotics and prebiotics, primarily improve the gut microbiota by supplementing with exogenous beneficial bacteria or promoting their proliferation. However, existing products mostly use strains derived from Western populations, which may have insufficient colonization and adaptability in the gut of Chinese populations; moreover, simply regulating the flora ignores the fundamental physiological differences in the individual's "spleen and stomach," making it difficult to maintain and stabilize the effects.

[0004] Therefore, there is an urgent need in this field for a technical solution that can overcome the above-mentioned deficiencies: a composite product that can combine the holistic conditioning concept of traditional Chinese medicine with modern precision microecological regulation, which can target the fundamental pathogenesis of "spleen deficiency", quickly and accurately improve the intestinal flora environment, and is particularly suitable for the physical characteristics of Chinese people.

[0005] Relevant patent documents retrieved: This document, published in China (CN104001098A) on August 27, 2014, discloses a traditional Chinese medicine for treating childhood anorexia. The medicine is made from the following raw materials: processed Codonopsis pilosula, stir-fried Atractylodes macrocephala, Poria cocos, stir-fried Dioscorea opposita, Pogostemon cablin, Aucklandia lappa, Astragalus membranaceus, Citrus aurantium, stir-fried Dolichos lablab, charred Crataegus pinnatifida, stir-fried Hordeum vulgare, stir-fried Massa fermentata, stir-fried Raphanus sativus, Amomum villosum, chicken gizzard lining, and processed Glycyrrhiza uralensis. The beneficial effects of this document are that the above-mentioned drugs are combined to treat diseases, symptoms, and diseases of the digestive system, achieving the effects of invigorating qi and strengthening the spleen, nourishing the stomach and promoting appetite, eliminating food stagnation and bloating, regulating the internal organs, and enhancing the body's immunity. The efficacy is reliable and without side effects.

[0006] This document, published in China (CN102441134A) on May 9, 2012, discloses a traditional Chinese medicine composition comprising Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Ziziphus jujuba, Codonopsis pilosula, Poria cocos, Dioscorea opposita, Glycyrrhiza uralensis, Aucklandia lappa, Amomum villosum, Myristica fragrans, Bletilla striata, Cuttlebone, Coptis chinensis, Crataegus pinnatifida, Hordeum vulgare, Citrus reticulata, Schisandra chinensis, Iris tectorum, Raphanus sativus, Gallus gallus domesticus gizzard lining, and Medicated Leaven. It also discloses the preparation of this traditional Chinese medicine composition and its preparation method. The traditional Chinese medicine composition and its preparation of this invention can be used to prepare drugs for treating spleen and stomach diseases such as gastritis, antral gastritis, chronic gastritis, spleen and stomach weakness, indigestion, halitosis, constipation, and hemorrhoids.

[0007] This document, published in China (CN108404099A) on August 17, 2018, discloses a dehumidifying and slimming oral liquid and its preparation method. The dehumidifying and slimming oral liquid comprises the following ingredients in parts by weight: 3-20 parts dried tangerine peel, 6-20 parts Poria cocos, 6-20 parts Plantago asiatica, 6-20 parts ginseng, 10-60 parts stir-fried Atractylodes macrocephala, 6-30 parts stir-fried Dioscorea opposita, 6-20 parts Codonopsis pilosula, 6-50 parts raw Astragalus membranaceus, 3-15 parts Polyporus umbellatus, 3-15 parts Pinellia ternata, 3-15 parts licorice root, 6-25 parts stir-fried Coix lacryma-jobi, 6-30 parts Euryale ferox, 6-50 parts roasted Astragalus membranaceus, 6-30 parts charred hawthorn, 6-30 parts charred Shenqu (medicated leaven), 6-30 parts charred malt, and 3-15 parts fresh ginger. The oral liquid for dehumidification and weight loss described in this literature is suitable for obese patients with spleen deficiency and dampness, phlegm-dampness, or qi deficiency. It enhances the body's gastrointestinal metabolism by using traditional Chinese medicine to replenish qi, promote diuresis and eliminate dampness, and dry dampness and resolve phlegm, thereby achieving a weight loss effect. The characteristics of this literature are that it does not require dieting, strenuous exercise, or laxatives, and the weight loss effect is good.

[0008] The document, published in China (CN112006137A) on December 1, 2020, discloses a spleen-strengthening and stomach-nourishing radish tea, comprising: 30-1000 parts roasted tea, 5-100 parts perilla, 3-100 parts radish seeds, 1-50 parts each of the following ingredients: Codonopsis pilosula / Codonopsis pilosula / Astragalus membranaceus / Lycium barbarum / Kudzu root / Angelica sinensis / Prunus armeniaca / Amomum villosum / Hippophae rhamnoides / Prunus mume / Taraxacum mongolicum / Chrysanthemum morifolium / Lilium brownii / Longan aril / Dried ginger / Lotus seed / Glycyrrhiza uralensis, and 1-50 parts each of Dioscorea opposita / Poria cocos / Crataegus pinnatifida / Horse malt / Medicated leaven. / Chicken gizzard / 3-100 parts jujube, 1-20 parts ginseng, 1-30 parts American ginseng, 1-30 parts Ganoderma lucidum, 3-50 parts white hyacinth bean, 5-100 parts coix seed, 3-50 parts nutmeg, 1-30 parts clove, 3-50 parts lemon, 3-50 parts Buddha's hand, 3-50 parts papaya, 1-30 parts patchouli, 1-100 parts dried tangerine peel, 1-100 parts germinated barley, 1-30 parts rose, 1-100 parts chicory, 1-30 parts galangal, 3-50 parts fox nut.

[0009] The document, published in China (CN105878898A) on August 24, 2016, discloses a pediatric spleen-strengthening and diarrhea-relieving powder composed of the following medicinal materials: American ginseng, Amomum villosum, Codonopsis pilosula, Pseudostellaria heterophylla, stir-fried Shenqu (medicated leaven), lotus seed, stir-fried Atractylodes macrocephala, stir-fried malt, stir-fried yam, charred hawthorn, morel mushroom, stir-fried hyacinth bean, stir-fried germinated barley, stir-fried coix seed, charred areca nut, kudzu root, Acorus tatarinowii, Cyperus rotundus, Polyporus umbellatus, tangerine peel, stir-fried white peony root, nutmeg, cuttlefish bone, Fritillaria thunbergii, Alisma plantago-aquatica, Terminalia chebula, Pogostemon cablin, poppy husk, stir-fried Shenqu (medicated leaven), costus root, cinnamon, Coptis chinensis, Quisqualis indica, Magnolia officinalis, Poria cocos, Plantago asiatica, Atractylodes lancea, prepared licorice root, dried plum, Cimicifuga foetida, chicken gizzard lining, Pinellia ternata, Areca peel, and stir-fried Citrus aurantium. The Pediatric Spleen-Strengthening and Diarrhea-Stopping Powder mentioned in this literature, also known as Spleen-Strengthening and Stomach-Benefiting Powder, is not only highly effective in treating diarrhea in children, but also shows remarkable efficacy in treating chronic diarrhea in adults.

[0010] The country of publication is China, publication number CN120682327A, publication date 2025.09.23. This document discloses that the surface protein of Lactobacillus paracasei K56 has one or more uses selected from the following (1)-(2): (1) to promote the proliferation of beneficial intestinal bacteria; (2) to help regulate the intestinal flora, wherein the regulation of the intestinal flora is to promote the proliferation of beneficial intestinal bacteria. Summary of the Invention

[0011] The purpose of this invention is to provide: A compound preparation based on the theory of spleen and stomach in traditional Chinese medicine and the relationship between intestinal flora balance, and related technologies, to solve technical problems such as regulating spleen and stomach function, balancing intestinal flora, assisting in regulating metabolism, and improving safety, or a combination thereof.

[0012] Terminology Explanation: Unless otherwise defined, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this subject matter pertains. Unless otherwise stated, all patents, patent inventions, and disclosures cited throughout this document are incorporated herein by reference in their entirety. Where multiple definitions exist for terms herein, the definitions provided in this chapter shall prevail.

[0013] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0014] Definitions of standard chemical terms can be found in the references "Functional Food Science" (Xiao Gongnian and Chu Bingquan, China Light Industry Press, 2024) and "Health Food Science" (Chi Yujie, China Light Industry Press, 2026).

[0015] Unless otherwise specified, conventional methods within the scope of the art, such as plate coating counting, in vitro digestion barrier simulation test, and extract determination, shall be used.

[0016] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0017] The “range” disclosed in this document takes the form of a lower limit and an upper limit. It can be one or more lower limits and one or more upper limits, respectively. A given range is defined by selecting a lower limit and an upper limit. The selected lower and upper limits define the boundaries of the particular range. All ranges that can be defined in this way are inclusive and composable; that is, any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a specific parameter, it is also expected that ranges of 60-110 and 80-120 are also expected. Furthermore, if the minimum range values ​​are listed as 1 and 2, and if the maximum ranges are listed as 3, 4, and 5, then the following ranges are all expected: 1-2, 1-4, 1-5, 2-3, 2-4, and 2-5.

[0018] In this invention, unless otherwise specified, the numerical range "ab" represents a shortened representation of any combination of real numbers from a to b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" have been listed in this document, and "0-5" is simply a shortened representation of these numerical combinations.

[0019] The term "functional food" used in this article refers to a special type of food that, according to relevant national standards for functional foods, uses ordinary food ingredients as a base, adds functional components such as probiotics and food-medicine homologous ingredients, has the function of regulating human physiological functions and improving specific physiological states, is not intended to treat diseases, is suitable for long-term consumption by specific groups of people, can be labeled with corresponding health care functions, and meets national food safety standards. It is distinct from ordinary basic foods and medicines.

[0020] The term "health products" used in this article refers to health foods that are registered / filed by the State Administration for Market Regulation, have clearly defined suitable and unsuitable populations, prescribed health benefits, and standardized dosages, aim to regulate bodily functions, contain functional ingredients (including probiotics, traditional Chinese medicine extracts, etc.), and are packaged with the blue hat logo. These foods cannot replace medication for treating diseases.

[0021] The term "microbial preparation" as used in this article refers to: a live / inactivated bacterial preparation made from beneficial microorganisms (mainly probiotics) and their metabolites and fermentation substrate as core effective components, prepared through processes such as cultivation, centrifugation, concentration, drying, and compounding, which can be taken orally and act on the human intestine to regulate the balance of intestinal microecology. It is the core functional ingredient of the probiotic food of this invention.

[0022] The term "spleen and stomach dysfunction" used in this article refers to a general term for common syndromes in traditional Chinese medicine, caused by factors such as improper diet, invasion of dampness, dysbiosis, physical weakness and fatigue, which damage the spleen and stomach's digestive function. Typical manifestations include abdominal distension, loss of appetite, food stagnation after meals, loose or sticky stools, heaviness in the body, and indigestion. These correspond to gastrointestinal discomfort related to intestinal digestive and absorptive dysfunction and intestinal flora imbalance in modern medicine.

[0023] The term "strengthening the spleen" as used in this article refers to a traditional Chinese medicine treatment method that uses a combination of food-grade medicinal ingredients and probiotics to nourish and restore the spleen's function of transporting and transforming food and the stomach's function of receiving food, thereby improving the spleen and stomach's weakness, enhancing the digestive and absorptive capacity of the intestines and stomach, and relieving spleen deficiency-related discomforts such as poor appetite, fatigue, and loose stools, thus improving spleen and stomach imbalances from the root cause.

[0024] The term "digestive aid" used in this article refers to a traditional Chinese medicine term that describes the components that can accelerate gastrointestinal motility, promote the secretion of digestive juices, break down food stagnation and food accumulation in the stomach and intestines, eliminate indigestion symptoms such as bloating, belching, food accumulation, and postprandial fullness, and work synergistically with probiotics to improve the efficiency of food decomposition and metabolism.

[0025] The term "dampness removal" used in this article refers to the conditioning effect of traditional Chinese medicine, which targets the stagnation of water and dampness in the body caused by spleen and stomach disorders. It improves symptoms of dampness such as sticky stools, heaviness in the body, abdominal distension due to phlegm and dampness, and thick and greasy tongue coating by using medicinal and food ingredients to transport and transform water and dampness, thereby reducing the damage of dampness to the intestinal microenvironment and assisting probiotics in stabilizing the intestinal environment.

[0026] The term "TCM syndrome" used in this article refers to the comprehensive summary of human diseases and sub-health states in TCM, which combines symptoms, signs, tongue and pulse, and constitution to determine the pathogenesis of the body. In this invention, it specifically refers to three types of syndromes related to intestinal digestion: spleen and stomach weakness, dampness obstructing the middle jiao, and food stagnation. These are the criteria for determining the target population for the product.

[0027] The term "intestinal flora imbalance" used in this article refers to a pathological / sub-healthy state in which the proportion, species structure, and metabolic homeostasis of beneficial bacteria, harmful bacteria, and neutral bacteria in the human gut are disrupted. It manifests as a decrease in the abundance of beneficial bacteria, excessive proliferation of pathogenic bacteria, and a reduction in beneficial metabolites such as short-chain fatty acids, accompanied by poor digestion, diarrhea, constipation, and abdominal distension, which correspond to the external manifestations of spleen and stomach disorders in traditional Chinese medicine.

[0028] The term "probiotics" as used in this article refers to live microorganisms that meet the definition in the "Regulations on the Application and Review of Probiotic Health Foods," and that, after being ingested in sufficient doses, can colonize the human gut, regulate the balance of gut microbiota, and produce health benefits to the host. These include compliant strains such as Lactobacillus, Bifidobacterium, and Bacillus, which are the core functional strains of this invention.

[0029] The term "prebiotic" used in this article refers to a class of functional oligosaccharide / polysaccharide carbohydrates that cannot be digested and absorbed by the human body but can reach the large intestine directly. They are not broken down by human stomach acid or digestive enzymes, and can selectively stimulate the growth and reproduction of probiotics in the intestine, enhance the colonization ability of probiotics, and are the exclusive nutritional substrate for probiotics.

[0030] The term "exogenous beneficial bacteria" used in this article refers to live probiotics that are not natively carried in the human gut and are introduced into the digestive tract through oral food or preparations. They are distinct from the innate endogenous gut flora and can quickly replenish the total amount of beneficial bacteria in the gut, thus improving gut flora imbalance.

[0031] The term "proliferation" used in this article refers to the process by which probiotics divide and grow in a suitable intestinal environment or in vitro fermentation substrate, utilizing prebiotics and nutrient substrates, resulting in a continuous increase in the number of live bacteria and an increase in the abundance of the bacterial community; it is divided into two categories: in vitro fermentation proliferation and in situ proliferation in the human intestinal tract.

[0032] The term "colonization rate" used in this article refers to the ratio of the number of live bacteria that successfully survive, adhere to, and colonize the intestinal mucosal epithelial cells after oral exogenous probiotics pass through the digestive barrier of gastric acid and bile to the total number of live bacteria initially ingested; the higher the value, the better the probiotics are resistant to digestion and have a better intestinal retention effect.

[0033] The term "probiotic strain" as used in this article refers to a single strain of probiotic species that has independent genetic characteristics, a clearly numbered label, and has been verified for safety and efficacy. Different strains of the same species may have different effects. This invention limits the specific strains that have the functions of strengthening the spleen and promoting digestion and regulating the intestinal flora.

[0034] The term "decoction" used in this article refers to the extraction process of Chinese medicinal and edible raw materials, which involves mixing herbal raw materials with purified water and extracting them by heating and boiling at a constant temperature to dissolve the active ingredients in the raw materials that have the effects of strengthening the spleen, promoting digestion, and removing dampness, thus obtaining a herbal extract.

[0035] The term "concentration" as used in this article refers to the process of heating the herbal extract obtained by decoction at low temperature and negative pressure to remove excess water, increase the concentration of active ingredients, reduce the volume of the liquid, and facilitate subsequent purification and concentration with probiotic powder. Temperature is controlled throughout the process to avoid damage to heat-sensitive active substances.

[0036] The term "drying" as used in this article refers to the preparation process in which concentrated herbal extracts are mixed with probiotic protective carriers, and then low-temperature drying processes such as spray drying and vacuum freeze drying are used to remove free moisture from the materials, producing stable solid powders, reducing water activity, and ensuring the long-term survival rate of probiotics.

[0037] In a first aspect, the present invention provides: a compound preparation comprising: prebiotics, probiotics and food-grade ingredients.

[0038] The prebiotics include at least three of the following: xylooligosaccharides, resistant dextrin, fructooligosaccharides, polydextrose, isomaltitol, and inulin. Preferably, the prebiotic is a combination of xylooligosaccharides, resistant dextrin, fructooligosaccharides, polydextrose, isomaltitol, and inulin. More preferably, the prebiotic comprises the following components by weight: 1-5 parts of xylooligosaccharides, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, or any range derived thereof; 3-10 parts of resistant dextrin, for example, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, or any range derived therefrom; Fructooligosaccharides 2-8 parts, such as 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, or any range derived thereof; Polydextrose 2-8 parts, for example 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, or any range derived therefrom; Isomaltitol 1-5 parts, for example 1 part, 2 parts, 3 parts, 4 parts, 5 parts, or any range derived thereof; Inulin 1-5 parts, for example 1 part, 2 parts, 3 parts, 4 parts, 5 parts, or any range derived therefrom.

[0039] The probiotics include at least three proprietary probiotic strains derived from the gut of healthy Chinese people and traditional fermented foods. Specifically, the probiotics are selected from Lactobacillus paracasei Zhang ( Lacticaseibacillus paracasei Zhang (CGMCC No. 5469), Bifidobacterium animalis subsp. lactis ( Bifidobacterium animalis subsp. lactis V9 (CGMCC No. 5470), Bifidobacterium longum subsp. infantis ( Bifidobacterium longum subsp. infantis At least one of B8762 (CGMCC No. 22765); Preferably, the probiotics are a combination of Lactobacillus paracasei Zhang, Bifidobacterium animalis subsp. lactis V9, and Bifidobacterium longum subsp. infantis B8762. More preferably, the probiotics, by weight, include 1-5 parts of *Lactobacillus paracasei* Zhang, 1-5 parts of *Bifidobacterium animalis* subsp. *lactobacterium* V9, and 1-5 parts of *Bifidobacterium longum* subsp. *infant* B8762.

[0040] Preferably, the ratio of live bacteria counts of each strain in the probiotics is between 1:1 and 5:1-5, for example, 1:1:1, 1:2:2, 1:3:3, 1:4:4, 1:5:5, or any range derived therefrom.

[0041] In some specific embodiments, the total viable count of the probiotics in the compound preparation is not less than 1.0 × 10⁻⁶. 9 CFU / g.

[0042] The medicinal and edible ingredients include two or more of the following: hawthorn, dried tangerine peel, codonopsis, malt, poria cocos, dried ginger, and licorice. Preferably, the medicinal and edible raw materials are a combination of hawthorn, dried tangerine peel, codonopsis, malt, poria cocos, dried ginger, and licorice. More preferably, the medicinal and edible raw material comprises the following components by weight: 10-25 portions of hawthorn, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 portions, or any range derived thereof; 5-25 portions of dried tangerine peel, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 portions, or any range derived thereof; Codonopsis pilosula, 6-25 parts, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 parts, or any range derived therefrom; Malt 10-25 parts, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 parts, or any range derived thereof; Poria cocos 6-20 parts, such as 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, or any range derived therefrom; 3-10 parts of dried ginger, for example, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, or any range derived therefrom; Add 3-20 parts of licorice, for example, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, or any range derived therefrom.

[0043] More preferably, the medicinal and edible ingredients, by weight, include: 21 parts hawthorn, 13 parts dried tangerine peel, 19 parts codonopsis, 21 parts malt, 11 parts poria cocos, 5 parts dried ginger, and 11 parts licorice.

[0044] In some specific embodiments, the compound formulation, by weight, comprises the following components: Prebiotics 5-30 servings, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 servings, or any range derived therefrom; Probiotics 1-15 parts, such as 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, or any range derived therefrom; 5-25 parts of ingredients that are both food and medicine, such as 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, or any range derived therefrom; Preferably, the compound preparation comprises, by weight, 25 parts prebiotics, 5 parts probiotics, and 20 parts food-medicine homologous ingredients.

[0045] In some specific embodiments, the dosage form of the compound preparation includes powder, granules, tablets, effervescent tablets, chewable tablets, hard capsules, soft capsules, oral liquids, suspensions, concentrated pastes, solid beverages, compressed candies, or a compound dosage form made by combining any two or more of the above dosage forms. Preferably, the dosage form of the compound preparation is a powder.

[0046] Secondly, the present invention provides a method for preparing the compound formulation, comprising the steps of: (1) The medicinal and edible raw materials are dissolved in a solvent, and then extracted, concentrated, dried and pulverized to obtain the processed medicinal and edible raw materials; (2) The processed medicinal and edible raw materials obtained in step (1) are mixed with prebiotics and probiotics to obtain the final product.

[0047] The solvent in step (1) is selected from at least one of water, ethanol, methanol, propanol, and ethyl acetate; Preferably, the solvent in step (1) is water.

[0048] Among them, the extraction method described in step (1) is decoction; In some specific implementations, step (1) includes a soaking step before extraction.

[0049] Wherein, the drying temperature in step (1) is 40-60℃, for example 40℃, 41℃, 42℃, 43℃, 44℃, 45℃, 46℃, 47℃, 48℃, 49℃, 50℃, 51℃, 52℃, 53℃, 54℃, 55℃, 56℃, 57℃, 58℃, 59℃, 60℃, or any range derived thereof; Preferably, the drying temperature in step (1) is 50°C.

[0050] Wherein, the particle size of the crushing in step (1) is 60-120 mesh, such as 60 mesh, 61 mesh, 62 mesh, 63 mesh, 64 mesh, 65 mesh, 66 mesh, 67 mesh, 68 mesh, 69 mesh, 70 mesh, 71 mesh, 7 mesh 2 mesh, 73 mesh, 74 mesh, 75 mesh, 76 mesh, 77 mesh, 78 mesh, 79 mesh, 80 mesh, 81 mesh, 82 mesh, 83 mesh, 84 mesh, 85 mesh, 86 mesh, 87 mesh, 88 mesh, 89 mesh, 90 mesh, 91 mesh, 92 mesh, 93 mesh, 94 mesh, 95 mesh, 96 mesh, 97 mesh, 98 mesh, 99 mesh, 100 mesh, 101 mesh, 102 mesh, 103 mesh, 104 mesh, 105 mesh, 106 mesh, 107 mesh , 108 mesh, 109 mesh, 110 mesh, 111 mesh, 112 mesh, 113 mesh, 114 mesh, 115 mesh, 116 mesh, 117 mesh, 118 mesh, 119 mesh, 120 mesh, or any derivative thereof; Preferably, the particle size of the pulverized material in step (1) is 80-100 mesh.

[0051] In some specific implementations, the mixing in step (2) is divided into primary mixing and secondary mixing; The first mixing step involves mixing the processed food-medicine homologous raw materials obtained in step (1) with prebiotics to obtain a premix. The duration of a single mixing cycle is 15-45 minutes, for example, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, 33 minutes, 34 minutes, 35 minutes, 36 minutes, 37 minutes, 38 minutes, 39 minutes, 40 minutes, 41 minutes, 42 minutes, 43 minutes, 44 minutes, 45 minutes, or any range derived therefrom; Preferably, the duration of one mixing cycle is 30 minutes.

[0052] The secondary mixing involves mixing the probiotics with the premix obtained from the primary mixing. The duration of the secondary mixing is 5-30 minutes, for example, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, or any range derived therefrom; Preferably, the duration of the secondary mixing is 15 minutes.

[0053] The environmental requirements for mixing in step (2) are: temperature ≤ 20℃ and relative humidity ≤ 30%.

[0054] In some specific implementations, the probiotics in step (2) are in the form of probiotic freeze-dried powder; Preferably, the preparation steps of the probiotic freeze-dried powder include: centrifuging the fermentation broth of probiotics, resuspending it in a protectant, and freeze-drying it to obtain the product.

[0055] In some specific implementations, the prebiotic mentioned in step (2) is: the specific components of the prebiotic are physically mixed.

[0056] Thirdly, the present invention provides the application of the compound preparation in the preparation of functional foods or health products that improve spleen and stomach function, regulate intestinal flora, and assist in weight management.

[0057] Preferably, the application is as follows: prebiotics provide substrates for the proliferation of probiotics; after colonization, probiotics improve the intestinal environment and function, creating conditions for the recovery of spleen and stomach function; the food-grade medicinal ingredients that invigorate the spleen and replenish qi fundamentally enhance the body's metabolic capacity, providing a stable internal environment for the long-term colonization of probiotics. This compound preparation is significantly superior to any single module or traditional preparation in promoting the proliferation of beneficial bacteria, inhibiting pathogenic bacteria, and improving intestinal barrier function.

[0058] The phrase "the probiotics are selected from at least one of *Lactobacillus paracasei*, *Bifidobacterium animalis* subsp. *lactobacter*, and *Bifidobacterium longum* subsp. *infant*" is derived from the foregoing explanation and / or the "fermentation broth of *Lactobacillus paracasei* Zhang, *Bifidobacterium animalis* subsp. *lactobacter* V9, and *Bifidobacterium longum* subsp. *infant* B8762" in Example 1, the "freeze-dried powder of *Lactobacillus paracasei* Zhang" in Example 2, the "freeze-dried powder of *Bifidobacterium animalis* subsp. *lactobacter* V9" in Example 3, and the "freeze-dried powder of *Bifidobacterium longum* subsp. *infant* B8762" in Example 4. Therefore, those skilled in the art can reasonably infer that A, its subordinate concepts, its essentially equivalent technical means, and technical means that can replace it within the scope of conventional and common knowledge based on the existing level of technology should all fall within the protection scope of this invention.

[0059] The beneficial effects of this invention are as follows: The present invention has at least the following beneficial effects: (1) Theoretical integration and innovation, addressing both symptoms and root causes: For the first time, a triple synergistic model was constructed, which consists of "prebiotics improving the intestinal microenvironment → probiotics precisely regulating the microbiota structure → ginseng and poria herbal formula strengthening the spleen and replenishing qi to treat the root cause". This model is based on the dual theories of "spleen governs transportation and transformation" in traditional Chinese medicine and "microbiota-gut-brain / metabolic axis" in modern times. It not only solves the symptoms of intestinal microbiota imbalance, but also targets the root cause of spleen and stomach weakness, breaking the vicious cycle of "spleen deficiency → microbiota imbalance → worsening of spleen deficiency".

[0060] (2) Synergistic effect of the formulation: The three modules are not simply superimposed, but form a positive cycle: prebiotics provide substrates for the proliferation of probiotics; after the probiotics colonize, they improve the intestinal environment and function, creating conditions for the recovery of spleen and stomach function; the traditional Chinese medicine module that invigorates the spleen and replenishes qi fundamentally enhances the body's metabolic capacity, providing a stable internal environment for the long-term colonization of probiotics. In vitro and animal experiments show that the compound preparation is significantly better than any single module or traditional preparation in promoting the proliferation of beneficial bacteria, inhibiting pathogenic bacteria, and improving intestinal barrier function.

[0061] (3) Strong localization and adaptability: The selected probiotic strains are all isolated from the intestines of healthy Chinese people and have been verified by genomics and functional studies. They have strong resistance to gastric acid and bile salts, and their adhesion and colonization rate to intestinal epithelial cells of Chinese people is on average more than 30% higher than that of common imported commercial strains. The Shenling Herbal Formula is optimized based on the classic formula and is more suitable for the constitution of modern Chinese people who are "spleen deficiency often accompanied by dampness and stagnation", avoiding the greasy and cloying nature that hinders the stomach.

[0062] (4) High safety and wide applicability: All raw materials are permitted for use in food under national regulations, and the formulation is mild. The preparation can be made into various forms such as powder, granules, tablets or capsules. The taste can be adjusted through the prebiotic module, making it easy to accept and suitable for people who need long-term conditioning. Detailed Implementation

[0063] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0064] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0065] Specific raw material information is shown in Table 1: Table 1. Raw Material Information

[0066] Example 1: Preparation of compound formulation powder 1. Raw material preparation: Food and medicine homology raw materials (ginseng and poria herbal powder): according to the weight proportions of hawthorn 21 parts, dried tangerine peel 13 parts, codonopsis 19 parts, malt 21 parts, poria 11 parts, dried ginger 5 parts, and licorice 11 parts, soak, decoct, extract, concentrate, dry, and pulverize the washed raw materials for later use.

[0067] Probiotics (mixed freeze-dried powder): The fermentation broth of *Lactobacillus paracasei* Zhang, *Bifidobacterium animalis* subsp. *lactobacter* V9, and *Bifidobacterium longum* subsp. *infant* B8762 is centrifuged, resuspended in a protectant, and freeze-dried to prepare a mixed freeze-dried powder, ensuring that the total viable count of the three strains is not less than 1.0 × 10⁻⁶. 11 The concentrations are CFU / g, and the ratio is approximately 1:1:1.

[0068] Prebiotics: Mix thoroughly by weight ratio of xylooligosaccharide 3 parts, resistant dextrin 8 parts, fructooligosaccharide 5 parts, polydextrose 5 parts, and isomaltitol 3 parts.

[0069] 2. Mixing and Preparation: Weigh out 25 parts prebiotics, 5 parts probiotics, and 20 parts food-grade medicinal materials according to the specified weight ratio. In a clean environment with a temperature ≤20℃ and relative humidity ≤30%, first add the food-grade medicinal materials and prebiotics into a three-dimensional motion mixer and mix for 30 minutes until homogeneous. Then, slowly add the mixed freeze-dried probiotic powder and continue mixing for 15 minutes to ensure uniform mixing.

[0070] 3. Dispensing and Packaging: Dispense the mixed powder into 2.5g packets into aluminum foil bags, seal with nitrogen filling. The resulting product contains ≥2.0 × 10⁻⁶ live probiotics. 9 CFU / bag

[0071] Example 2: The only difference from Example 1 is that the probiotic is "Lactobacillus paracasei Zhang freeze-dried powder, ensuring that the total viable count of the strain is not less than 1.0 × 10⁻⁶". 11 "CFU / g", and all other conditions are basically the same as in Example 1.

[0072] Example 3 Compared with Example 1, the only difference is that the probiotic is "Bifidobacterium animalis subsp. lactis V9 freeze-dried powder, ensuring that the total viable count of the strain is not less than 1.0 × 10⁻⁶". 11 "CFU / g", and all other conditions are basically the same as in Example 1.

[0073] Example 4 Compared with Example 1, the only difference is that the probiotic is "Bifidobacterium longum subsp. infantis B8762 freeze-dried powder", ensuring that the total viable count of the strain is not less than 1.0 × 10⁻⁶. 11 "CFU / g", and all other conditions are basically the same as in Example 1.

[0074] Example 1: In vitro simulated gastrointestinal fluid tolerance test The preparation prepared in Example 1 was processed according to the in vitro simulated gastrointestinal fluid method in the Chinese Pharmacopoeia. The results showed that after digestion with simulated gastric fluid (pH 2.5, 2h) and simulated intestinal fluid (3h), the total survival rate of probiotics in the preparation was over 75%, which was significantly higher than that of the control single commercial strain powder (survival rate of about 50%). This indicates that the prebiotics and herbal components in the preparation of this invention played a good protective role in the survival of probiotics during digestion.

[0075] Example 2: Regulatory effect on spleen-deficiency model mice 1. Model Establishment and Grouping: A mouse model of spleen deficiency was established using the method of dietary indiscretion combined with overwork. Fifty mice were randomly divided into 5 groups: normal control group, model control group, compound probiotic combined with food and medicine homology group obtained in Example 1 (combined group), LC-Zhang combined with food and medicine homology group obtained in Example 2 (LC-Zhang group), B8762 combined with food and medicine homology group obtained in Example 4 (B8762 group), and V9 combined with food and medicine homology group obtained in Example 3 (V9 group).

[0076] 2. Indicator Monitoring: Four weeks after the intervention, the following indicators were monitored: Macroscopic indicators: mouse body weight, general condition score (the lower the score, the better the condition).

[0077] The results showed that, in general condition, the mice in the model control group exhibited typical symptoms of spleen deficiency, such as lethargy, reduced activity, brittle fur, and loose stools, with a general condition score of (10.20 ± 1.40) points, significantly higher than that of the blank control group (0.80 ± 1.03) points. The combined group of the present invention showed significant improvement in the above symptoms, with the score decreasing to (1.40 ± 1.26) points, demonstrating significantly better efficacy than the LC-Zhang group, V9 group, and B8762 group.

[0078] Scoring criteria: Based on the methods described in the literature, scores are given on four dimensions: mental state, activity level, coat luster, and fecal characteristics. Each item is scored from 0 to 3 points, for a total score of 0 to 12 points. Higher scores indicate more severe spleen deficiency symptoms.

[0079] Table 2. General condition scores of mice in each group

[0080] Body weight change: The body weight growth rate of mice in the model control group was only (21.31 ± 6.54)%, significantly lower than that of the blank control group (50.97 ± 8.62)%. The body weight growth rate of the combined group of the present invention recovered to (47.37 ± 8.26)% (P<0.001 vs model group), with no statistically significant difference compared with the blank control group (P>0.05), and significantly better than the single-strain V9 group and the single-strain B8762 group (P<0.01).

[0081] Table 3. Changes in body weight of mice in each group

[0082] Compared with the model group, the combined group of the present invention can significantly restore gut microbiota diversity and improve... Lactobacillus ( Lactobacillus ), Bifidobacterium ( Bifidobacterium The relative abundance of beneficial bacteria such as bacteria.

[0083] Table 4. Relative abundance (%) of gut microbiota genera in each group of mice

[0084] Case 3: Human Trial Observation One hundred volunteers meeting the diagnostic criteria for spleen deficiency with dampness and intestinal dysfunction were recruited and randomly divided into an experimental group and a control group. The experimental group took one sachet of the preparation of this invention (product of Example 1) twice daily; the control group took a placebo with the same appearance. The intervention period was 8 weeks.

[0085] The results showed that after 4 and 8 weeks of intervention, the improvement rates of major symptoms such as abdominal distension, loss of appetite, and irregular bowel movements in the experimental group were significantly better than those in the control group. P <0.05).

[0086] (1) Syndrome score: The total syndrome score of the experimental group decreased from (17.24±3.31) before intervention to (5.13±2.06) after 8 weeks of intervention, which was significantly better than (10.86±3.22) of the control group.

[0087] Table 5. Total syndrome scores before and after intervention in the two groups ( ±s)

[0088] (2) Improvement of main symptoms: After 8 weeks of intervention, the improvement rates of abdominal distension, loss of appetite and irregular bowel movements in the experimental group were 78.0%, 74.0% and 72.0%, respectively, which were significantly higher than those in the control group (36.0%, 32.0% and 34.0%).

[0089] Table 6. Improvement rate of main symptoms in the two groups (%)

[0090] Verification of technical effectiveness and / or analysis of technical problem solving This invention provides a compound preparation with sound theoretical basis, scientific formulation, clear synergistic effects, and suitability for the Chinese physique by organically combining prebiotics, localized probiotics, and optimized ginseng and poria cocos formula in specific proportions. This preparation can comprehensively regulate spleen, stomach, and intestinal functions at multiple levels from the "microenvironment-microbiota-host" level, and shows potential for auxiliary metabolic regulation, demonstrating promising prospects for development and application.

[0091] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A compound preparation, characterized in that, include: Prebiotics, probiotics, and food-grade ingredients; The medicinal and edible ingredients include two or more of the following: hawthorn, dried tangerine peel, codonopsis, malt, poria cocos, dried ginger, and licorice. The probiotics are selected from at least one of Lactobacillus paracasei, Bifidobacterium animalis subsp. lactis, and Bifidobacterium longum subsp. infantis. The prebiotics include at least three of the following: xylooligosaccharides, resistant dextrin, fructooligosaccharides, polydextrose, isomaltitol, and inulin.

2. The compound formulation according to claim 1, characterized in that, The prebiotics are a combination of xylooligosaccharides, resistant dextrin, fructooligosaccharides, polydextrose, isomaltitol, and inulin. The probiotics are a combination of Lactobacillus paracasei, Bifidobacterium animalis subsp. lactis, and Bifidobacterium longum subsp. infantis. The medicinal and edible ingredients are a combination of hawthorn, dried tangerine peel, codonopsis, malt, poria cocos, dried ginger, and licorice.

3. The compound formulation according to claim 2, characterized in that, The prebiotics, by weight, include 1-5 parts xylooligosaccharide, 3-10 parts resistant dextrin, 2-8 parts fructooligosaccharide, 2-8 parts polydextrose, 1-5 parts isomaltitol, and 1-5 parts inulin. The probiotics, by weight, include 1-5 parts of Lactobacillus paracasei, 1-5 parts of Bifidobacterium animalis subsp. lactis, and 1-5 parts of Bifidobacterium longum subsp. infantis. The medicinal and edible ingredients, by weight, include 10-25 parts hawthorn, 5-25 parts dried tangerine peel, 6-25 parts codonopsis, 10-25 parts malt, 6-20 parts poria cocos, 3-10 parts dried ginger, and 3-20 parts licorice.

4. The compound formulation according to claim 3, characterized in that, The medicinal and edible ingredients, by weight, include: 21 parts hawthorn, 13 parts dried tangerine peel, 19 parts codonopsis, 21 parts malt, 11 parts poria cocos, 5 parts dried ginger, and 11 parts licorice.

5. The compound formulation according to claim 1, characterized in that, The dosage forms of compound preparations include powders, granules, tablets, effervescent tablets, chewable tablets, hard capsules, soft capsules, oral liquids, suspensions, concentrated pastes, solid beverages, compressed candies, or compound dosage forms made by any combination of two or more of the above dosage forms. The ratio of live bacteria in each strain of the probiotic is 1:1-5.

6. The compound formulation according to claim 1, characterized in that, Based on weight, it includes 5-30 parts prebiotics, 1-15 parts probiotics, and 5-25 parts food and medicine ingredients.

7. The method for preparing the compound formulation according to any one of claims 1-6, characterized in that, Including the following steps: (1) The medicinal and edible raw materials are dissolved in a solvent, and then extracted, concentrated, dried and pulverized to obtain the processed medicinal and edible raw materials; (2) The processed medicinal and edible raw materials obtained in step (1) are mixed with prebiotics and probiotics to obtain the final product.

8. The preparation method according to claim 7, characterized in that, The solvent used in step (1) is selected from at least one of water, ethanol, methanol, propanol, and ethyl acetate; The extraction method described in step (1) is decoction; The drying temperature in step (1) is 40-60℃, and the particle size of the pulverized material in step (1) is 60-120 mesh.

9. The preparation method according to claim 7, characterized in that, The mixing in step (2) is divided into primary mixing and secondary mixing; The first mixing is: mixing the processed food-medicine homology raw material obtained in step (1) with prebiotics to obtain a premix; the second mixing is: mixing probiotics with the premix obtained in the first mixing; The probiotics mentioned in step (2) are in the form of probiotic freeze-dried powder; The prebiotic mentioned in step (2) is obtained by physically mixing the components of the prebiotic.

10. The use of the compound preparation according to any one of claims 1-6 in the preparation of functional foods or health products that improve spleen and stomach function, regulate intestinal flora, and assist in weight management.

Citation Information

Patent Citations

  • Chinese herbal medicinal composition, preparation, and preparation method and application thereof

    CN102441134A

  • Traditional Chinese medicine for treating infant anorexia

    CN104001098A

  • Pediatric spleen-tonifying and diarrhea-checking powder

    CN105878898A

  • Dehumidification weight reducing oral liquid and preparation method thereof

    CN108404099A

  • Spleen-tonifying and stomach-nourishing Zifu tea and preparation method thereof

    CN112006137A